Thermo Fisher Scientific Announces 800 Million Swiss Franc Bond Issuance
Thermo Fisher Scientific is issuing 800 million Swiss Francs in bonds across four tranches with maturities ranging from 3 to 12 years.
Stocks · News reference
Thermo Fisher Scientific Launches Value-Priced AmpSure Universal qPCR Master Mixes
Thermo Fisher Scientific has introduced its new Thermo Scientific AmpSure Universal SYBR Green and Probe Master Mixes, designed to provide a cost-effective option for laboratory qPCR applications.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Thermo Fisher Scientific Chief HR Officer Lisa P. Britt Sells Shares
Lisa P. Britt, Senior Vice President and Chief HR Officer of Thermo Fisher Scientific, sold 2,831 shares of company stock.
Thermo Fisher Scientific Executive Vice President Michael D. Shafer to Retire
Thermo Fisher Scientific announced that Executive Vice President Michael D. Shafer will retire at the end of 2026.
8-K filing — THERMO FISHER SCIENTIFIC INC. (TMO)
Filed: 2026-10-30 AccNo: 0000097745-26-000181 Size: 270 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
RMD Stock Up on Q1 Earnings and Revenue Beat, Gross Margin Climbs
ResMed (RMD) delivered solid first-quarter fiscal 2027 results with adjusted EPS of $2.91, up 14% year-over-year and beating consensus by 9%. Revenues grew 6% to $1.41 billion, driven by sustained demand for sleep devices and masks. Gross margins expanded 50 basis points to 62.5% from productivity gains. However, the company faced headwinds from discontinued Astral life-support device sales and the MatrixCare divestiture. RMD maintained its fiscal 2027 guidance for 5-7% core constant-currency revenue growth and $12.00-$12.25 adjusted EPS.
Thailand Next Generation Sequencing (NGS) Market Size, Share, Trends, and Forecast - 2026 to 2036 | Precision Medicine Drives 12.7% CAGR and a $305.21 Million Opportunity
Thailand's NGS market is projected to reach $305.21 million by 2036, growing at a 12.7% CAGR from $92.03 million in 2026. Growth is driven by the Genomics Thailand national precision medicine initiative, rising clinical adoption in oncology and rare diseases, expanded reimbursement under the Universal Coverage Scheme, and increasing demand for outsourced sequencing services. Commercial sequencing services and clinical applications in oncology are expected to be the fastest-growing segments.